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Increased bone aluminum deposition after subtotal parathyroidectomy
in dialyzed patients. Ten dialyzed patients underwent a systematic bone
biopsy before and 19 9 months after subtotal parathyroidectomy
(PTX). At the end of the follow-up period all the patients, except two,
who complained of proximal myalgia, were asymptomatic. Compared
to the bone biopsy specimen obtained prior surgery, decreased bone
formation without mineralization impairment was observed after PTX.
Despite an average decrease in aluminum gels intake after PTX, an
increase in stained aluminum was observed (0.69 0.79 versus 1.20
0.95 mmlmm2, P < 0.050). Aluminum accumulation depended on the
pre-PTX bone aluminum load: pre- and post-PTX bone aluminum loads
were correlated (r = 0.78, P < 0.01). Bone aluminum accumulation was
not related to the amount of aluminum gel intake after PTX; however,
only two patients free of both bone aluminum deposit prior to PTX and
aluminum gel intake after PTX had no stainable aluminum on the
second bone biopsy after PTX. The only patient who had no decrease
in bone formation after PTX had no increase in bone aluminum.
Assuming that the patients had no aluminum deposit prior to dialysis,
we measured the rate of bone aluminum accumulation. It rose from 0.11
0.09 mm/mm2/year prior to PTX to 0.40 0.25 mm/mm2/year after
PTX (P < 0.05) in the six patients who were maintained on phosphate
binders and who had a decrease in bone formation after PTX. These six
patients had unchanged aluminum gel intake. When considering pre-
and post-PTX bone histology independently, there was no relationship
between various parameters of bone formation and aluminum deposits;
markedly decreased bone formation also occurred in the two patients
without aluminum deposit post-PTX. In conclusion, when pre-existent
deposits and/or aluminum gels are prescribed, patients after parathy-
roidectomy develop an increase in bone aluminum deposition. It is
likely that low PTH levels resulting in low remodeling could facilitate
bone aluminum deposition; however, whether such aluminum deposit
plays a role in the bone abnormalities observed remains to be proven.
Augmentation des dépôts osseux d'aluminium après parathy-
roidectomie subtotale chez les patients dialyses. Dix malades dialyses ont
u une biopsie osseuse systématique avant et 19 9 mois après une
parathyroidectomie subtotale (PTX). A Ia fin de l'dtude, tous les
malades, sauf deux, étaient asymptomatiques. Comparativement a la
biopsie faite avant chirurgie, une diminution de Ia formation osseuse
sans trouble de Ia minéralisation a Cté observée aprês PTX. Malgré une
diminution de l'apport en gel d'aluminium, une augmentation de
['aluminium colorable osseux a ete observée (0.69 0.79 vs. 1.20
3.95 mm/mm2, P < 0.050). L'accumulation d'aluminium osseux
lCpendalt de son importance avant PTX: l'aluminium osseux avant et
après PTX Ctait corrélé (r = 0.78, P < 0.01). L'accumulation
J'aluminium osseux n'était pas liëe a Ia quantite de gels d'aluminium
ingCrés après PTX; cependant seuls deux malades qui n'avaient pas de
dépôts colorables osseux d'aluminium avant PTX et qui ne recurent pas
de gels d'aluminium apres PTX n'eurent pas de ddpôts colorables
osseux sur leur biopsie après PTX. Un des dix malades n'a pas diminué
sa formation après PTX et n'a pas augmenté ses dépôts osseux. Faisant
l'hypothese que les malades n'avaient pas de dépôts osseux d'alumi-
nium avant le debut de la dialyse, nous avons calculé la vitesse
d'accumulation de l'aluminium dans l'os. Celle-ci a augmenté de 0.11
0.09 mm/mm2/an avant PTX a 0.40 0.25, mm/mm2/an après PTX (P <
0.05) chez les six malades qui ont recus des gels d'aluminium et ont
diminué leur formation osseuse apres PTX. En moyenne l'apport en gel
d'aluminium n'a pas été modiflé chez ces six malades aprés PTX. Si l'on
considère l'histologie osseuse indCpendamment avant et apres PTX ii
n'y avait pas de relation entre les diffdrents paramètres de formation et
les dépôts d'aluminium; la formation osseuse était egalement très
diminuée chez les deux malades qui n'avaient aucun depot d'aluminium
aprés PTX. En conclusion, quand il y a depOts d'aluminium avant PTX
et que des gels d'aluminium sont prescrits, les malades dont la forma-
tion osseuse diminue, augmentent leur accumulation d'aluminium os-
seux. II est vraisemblable que des taux bas de PTH, entrainant une
diminution du remodelage osseux, facilitent l'accumulation d'alumi-
nium osseux; cependant, il n'est pas prouvé que ces depots aient un rOle
dans les anomalies osseuses observées chez ces malades.
An association between aluminum overload and dialysis
osteomalacia has been reported [1—2]. In dialyzed patients,
bone aluminum deposits are associated with reduced bone cells,
decreased bone formation, and a lack of histological features
characteristic of hyperparathyroidism [3—4]. Biochemical fea-
tures of such patients include an inappropriate low level of
serum immunoreactive parathyroid hormone (iPTH) [3—51.This
association of low serum iPTH level and bone aluminum
overload might be due to aluminum accumulation in parathy-
roid glands. Recent data show, in patients with dialysis
osteomalacia, parathyroid gland dysfunction exhibited by a
markedly diminished PTH response to hypocalcemia [6—7].
Furthermore, aluminum has been shown in vitro to decrease
PTH secretion [8]. However, it cannot be excluded that in
dialyzed patients, aluminum might accumulate in bone, as the
level of PTH secretion decreases. To test this hypothesis, we
studied the relationship between bone histology and bone
aluminum deposits in bone biopsy specimens from dialyzed
patients before and 19 months after parathyroidectomy.
Methods
Study design. In a dialysis center, ten patients had bone
biopsies prior to subtotal parathyroidectomy, as indicated by
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the presence of hypercalcemia, bone pain and/or aggravation of
radiological signs of osteitis fibrosa. The bone biopsy was
performed at the time of parathyroidectomy or, at the longest
delay, 2 months prior to surgery. Parathyroidectomy was
performed by heterotopic autotranspiantation in the forearm.
After informed consent was obtained, a second bone biopsy on
each patient was performed at the end of the study. At that time
all the patients were asymptomatic, except patients 5 and 7 who
complained of proximal myalgia. All patients were dialyzed in
the center with a dialysate aluminum content below 0.5
smoles/liter, checked each month.
Measurements. Serum calcium, phosphate, and alkaline
phosphatases levels are the average of three weekly consecu-
tive determinations. Serum 1PTH was determined before
parathyroidectomy with three different antibodies [9—11]. After
parathyroidectomy serum iPTH was always measured with a
sheep antibody directed against the fragment of 44—66 PTH [11].
Bone biopsy was performed after double tetracycline labeling
according to the schedule of 2 days on, 10 days off, and 2 days
on. Bone biopsy was performed 2 days after the last tetra-
cycline labeling. The first tetracycline label prior to
parathyroidectomy was ineffective for patients 4 and 10. On
three sections stained by toluidin blue trabecular bone volume
(TBV, %), osteoid surface (OS, %), osteoblastic surfaces (Obis,
mean osteoid thickness (MOT, pm), and osteoclastic resorp-
tion surfaces (ORS, %) were measured. On two unstained l0-s
thick sections mineralization rate (MR, jim/day) and the extent
of single (SLS, %) and double-labeled surfaces (DLS, %) were
measured. From these parameters we calculated formation at
tissue level (Svft, .t3/p?/day) as (DLS + X MR and
2 Svftformation at BMU level [Svf (BMU), 3/s2/day] as —. All
measurements were performed with an eye-piece graticule
(Zeiss Integral plate II, Zeiss, Oberkochen, Federal Republic of
Germany) except for MOT and MR which were measured
directly with a digitized image analyzer (Leitz ASM). Normal
values for static parameters have been published previously by
Bordier and Tun Chot [121. Normal values for MR, SLS, and
DLS were obtained from Melsen and Mosekilde [13]. From
these parameters normal values for Svft and Svf BMU were
calculated.
Bone aluminum stains were performed according to the
method described by Maloney et al [141. Stained trabecular
bone aluminum has been shown to correlate with bone alumi-
num content measured biochemically [2]. We determined the
percentage of trabecular surface stained with aluminum,
whether or not it was covered by osteoid, and all the aluminum
stained on trabecular bone (mm/mm2). Bone aluminum ac-
cumulation rate (mm/mm2/year) after parathyroidectomy was
calculated as the difference between the amount of trabecular
bone aluminum in the two biopsy specimens. Assuming that
there was no stainable aluminum prior to dialysis, the bone
accumulation rate prior to parathyroidectomy was calculated
by dividing the trabecular bone aluminum by the duration of
dialysis at this time. If there was aluminum in the bone before
dialysis began, this would have led to an overestimation of
aluminum accumulation rate.
Results are expressed by the mean SD. Wilcoxon test was
used for statistical comparison of pre- and post-parathyroid-
ectomy results and treatment. Linear regression analysis was
used to calculate the correlations. The slopes of the regression
lines were compared by Student's t test.
Results
Pertinent clinical and pre- and post-parathyroidectomy bio-
chemical data are detailed in Table 1. The average delay
between the second bone biopsy and parathyroidectomy was 19
9 months. After parathyroidectomy, serum calcium and
phosphate were unchanged whereas serum alkaline phospha-
tases were reduced markedly. Prior to parathyroidectomy se-
rum iPTH level, which is not reported in detail here because of
the different kind of antibodies used, was always elevated
markedly. After parathyroidectomy serum iPTH was in the
normal range in three patients and still increased in seven
patients.
The average pre- and post-parathyroidectomy treatment re-
ported (Table 1) deals with the 6-month period before
parathyroidectomy and excludes the 2-month period after
parathyroidectomy when larger doses of vitamin D derivatives
were required to maintain normal serum calcium. After this
delay, four patients were still treated with la(OH) vitamin D.
The mean intake of aluminum hydroxide gels was decreased
after parathyroidectomy (P < 0.05); three patients were not
taking any aluminum gels after the parathyroidectomy.
The pertinent bone histomorphometric data are presented in
Tables 2 and 3. The average results of the biopsies after
parathyroidectomy demonstrated a decrease in bone resorption
and also in the cellular parameters of bone formation as
demonstrated by the decreased extent of osteoblastic cell
surfaces. Double-labeled surfaces were reduced markedly as
illustrated in Figure 1. Mineralization rate, and thus exact bone
formation rate, could not be determined in four patients be-
cause of lack of detectable double-labeled surfaces on the
second bone biopsy. When measurable, the mineralization rate
was unchanged after parathyroidectomy. Average bone forma-
tion at tissue level was reduced after parathyroidectomy and in
seven of ten patients was more than 1 SD below the normal
mean (Table 3). Decreased bone formation at BMU level was
associated with reduced osteoid thickness. After parathyroid-
ectomy, there was no significant relation between serum iPTH
and bone resorption or formation.
These features were associated with an average increase in
bone aluminum deposit as shown in the percentage of stained
trabecular surfaces or in the trabecular aluminum in mm/mm2
(Fig. 2).
There was a correlation between the aluminum-stained sur-
faces and the trabecular bone aluminum before (r 0.66, P <
0.01) and after (r = 0.89, P <0.01) parathyroidectomy. How-
ever, the slopes of the two regression lines were different (P <
0.05), and there was a higher amount of deposit at the trabecular
surfaces (aluminum-stained surfaces) for a given quantity of
trabecular aluminum after parathyroidectomy (Fig. 4). Post-
parathyroidectomy aluminum deposits were not correlated with
the daily intake of aluminum gels, the delay since surgery, or
with serum iPTH level. Pre- and post-bone aluminum deposits,
whether determined as the percentage of stained trabecular
surfaces or as total trabecular aluminum, were correlated (r =
0.78, P < 0.01 and r = 0.82, P < 0.01). Individual data,
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Table 1. Clinical and biochemical data
Abbreviation: PTX, subtotal parythyroidectomy
a The normal value for alkaline phosphatases is 660 to 1300 nkatlliter.
b The normal value for serum iPTH is 76 to 325 pg/mI.
The significant difference between pre- and post-PTX results is P < 0.01.
' P < 0.05 between pre- and post-PTX results.
displayed in Table 3 and in Figures 2 and 3, provide further
information. Patients 4 and 10 had no aluminum deposits on the
first biopsy, and did not take any aluminum gel after
parathyroidectomy. These two patients did not exhibit alumi-
num deposit on the second biopsy post-parathyroidectomy. The
third patient (2) who did not take phosphate binders post-
parathyroidectomy, had marked aluminum deposit prior to
parathyroidectomy; aluminum-stained trabecular surfaces but
not trabecular-stained aluminum increased after surgical inter-
vention (Fig. 2). Patient 9 had no suppression of histological
parameters of secondary hyperparathyroidism and still had high
bone formation on the second biopsy (Fig. 3); in addition, he
had no significant increase in bone aluminum deposit (Fig. 2). If
considered independently, these four patients (2, 4, 9, and 10)
had no significant rise in stainable bone aluminum.
When considering the ten patients, bone aluminum accumula-
tion rate was not significantly different before (0.11 0.15
mm/mm2/year) and after (0.22 0.28 mm/mm2/year)
parathyroidectomy. However, if patients 2, 4, and 10 free of
aluminum gel intakes since parathyroidectomy and the fourth
patient (9) who did not decrease bone formation rate were
excluded, the mean aluminum accumulation rate rose from 0.11
0.09 to 0.40 0.25 mm/mm2/year (N = 6, P < 0.05). In these
six patients, average post-parathyroidectomy aluminum intake
was unchanged compared to pre-parathyroidectomy.
Prior to parathyroidectomy, six out of the ten patients
exhibited aluminum deposits in the bone biopsy specimens. In
both the pre- and post-parathyroidectomy biopsy specimens,
the amount of the aluminum deposit was not correlated with the
duration of the dialysis or with cellular or dynamic parameters
Fig. 1. Unstained Section of the post-parathyroidectomy bone biopsy
specimen of one patient (x40). Much single and double tetracycline
labeling corresponding to the double-labeling given prior PTX are
observed inside trabecular bone (); only single tetracycline labeling
corresponding to the second tetracycline double-labeling given prior to
this second bone biopsy are observed at the edge of trabeculae (p).
of bone formation. However, when considering both the pre-
and post-parathyroidectomy data together, osteoblastic sur-
faces and stained aluminum surfaces were negatively correlated
(r = 0.51, N = 20, P < 0.01). After parathyroidectomy two
patients without aluminum deposits on the second biopsy were
not different from the whole group concerning markedly re-
duced bone formation.
Serum Alkaline Serum
Treatment
Aluminum
Pa- Age/
Dura-
tion of
dialysis
Delay
after
PTX
Serum calcium
mmoles/liter
Pre- Post-
phosphate
mmoles/liter
Pre- Post-
phosphatase
nkat/litera
-•—
Pre- Post-
iPTH
pg/mi"
Post-
hydroxide
giday
Pre- Post-
Vitamin D derivatives
jig/day
tient sex years months PTX PTX PTX PTX PTX PTX PTX PTX PTX Pre-PTX Post-PTX
1 65/F 9 14 2.70 2.54 1.88 1.56 1582 1000 246 6 3 — —
2 70/F 4 6 2.69 2.33 1.12 2.28 3374 1946 843 6 0 — I a OH D
0.25
3 60/F 4 30 2.54 2.58 1.64 1.82 4086 1131 345 3 4 25 OH D —
50
4 24/F 6 9 2.37 1.75 2.12 1.58 2095 647 795 2 0 — 1 a OH D
1
5 67/M 10 22 2.60 2.47 2.85 2.36 3800 1073 3500 6 6 — —
6 47/M 7 26 2.57 2.46 1.86 1.81 1709 841 3325 12 8 — —
7 54/M 9 18 2.47 2.50 1.66 1.72 934 469 200 6 5 25(OH) D 1 a OH D
25 0.25
8 36/M 6 34 2.07 2.10 3.68 2.70 1251 801 2135 2 1 — —
9 55/F 8 22 2.42 2.43 1.61 1.63 2600 2410 2937 6 6 — —
10 39/M 2 11 2.39 2.32 1.98 1.34 5400 2597 250 4 0 25 OH 1 a OH D
25 2
Mean 51.7 6.5 19 2.48 2.34 2.03 1.84 2683 1291" 1458 5.3 33e
SD ±15.0 ±2.6 ±9 ±1.85 ±0.25 ±0.72 ±0.35 ±1441 ±751 ±1369 ±2.9 ±2.9
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Table 2. Average pre- and post-parathyroidectomy bone biopsy dataa
TBV
%
RS
%
ROY
%
OS
%
ObS
%
MOT
/Lm
Before PTX 24.8
(N =
8,2
10)
6.6
(N =
2.6
10)
9.2 5,5 45.3
(N =
17.8
10)
16.0 8.0
(N = 10)
11.8 3.4
(N = 10)
After PTX 25.5
(N =
10.4
10)
1.5
(N =
1.6
10)
7.7 9.0 52.3
(N =
25.4
10)
4.0 5,7c
(N = 10)
8.8 3.2c
(N = 10)
Normal values: mean SD 19.3 1.3e 0.51 0.14 2.5 1.0 17.9 1.2 5.4 l.9 9.5 0.7
Abbreviations: TBV, trabecular bone volume; RS, resorption surfaces; ROY, relative osteoid volume; OS, osteoid surface; ObS, osteoblastic
surfaces; MOT, mean osteoid thickness; SLS, single-labeled surfaces; DLS, double-labeled surfaces; MR, mineralization rate; Svft, formation at
tissue level; Als, trabecular surface stained with aluminum; TAL, aluminum stained on trabecular bone; Bone al ac rate, bone aluminum
accumulation rate.
The results are expressed as mean SD.
b P < 0.05.
P = 0.02 between pre- and post-parathyroidectomy results.
d The data excludes patients without double surfaces from the calculation of the mean.
The data are taken from Bordier and Tunchot [12].
The data are taken from Melsen and Mosekilde [131.
Fig. 2. Evolution of pre- and post-parathyroidectomy stainable bone
aluminum evaluated whether as the percentage of stained trabecular
surfaces or as total trabecular aluminum. Symbols are: A, patient 9
who had no significant decrease in bone formation after parathy-
roidectomy; A, patients 2, 4, and 10, who were not prescribed alumi-
num gel after parathyroidectomy; 0 P < 0.05.
Discussion
Subtotal parathyroidectomy, in dialyzed patients with refrac-
tory secondary hyperparathyroidism, results in marked clinical,
biochemical, and radiological improvement [15]. This improve-
ment is expected from the decrease of the well known hyper-
resorptive effect of PTH; however, recent histomorphometric
studies have stressed a positive role for PTH on bone formation
and mineralization in dialyzed patients [16—17]. Corroborating
this last statement, few cases of osteomalacia following
parathyroidectomy have been reported [18—19]. However, our
present study, including bone biopsy specimens of all patients
who had undergone parathyroidectomy, revealed that parathy-
roidectomy induced decreased formation without overt
osteomalacia. This lack of mineralization defect can be as-
sumed from decreased mean osteoid thickness associated with
Fig. 3. Evolution of bone formation rate in the six patients in whom
double-labeled surfaces persisted after parathyroidectomy. The symbol
A represents patient 9 who had no significant decrease in bone
formation after parathyroidectomy.
a decrease in bone formation. Only one out of the ten patients
(10) had the two histological criteria for osteomalacia—de-
creased formation at tissue level associated with high osteoid
thickness; prior to parathyroidectomy, this patient had a high
mean osteoid thickness which did not increase after
parathyroidectomy.
Bone formation which was, on the average, above normal
values before parathyroidectomy, decreased to pathologically
low range in seven of the ten patients. This was due to a
01
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SLS
%
DLS
%
MR Svft Als
j.dday p?/2/day
TA1
mm/mm2
Bone a! ac
rate
mm/mm2/year
27.4 13.7 18.7 10.5 0.97 0.32 0.333 0.253 11.6 17,1 0.69 0.79 0.11 0.15
(N = 8) (N = 8) (N = 8) (N 8) (N = 10) (N = 10) (N = 10)
8.1 11.6b 5.3 8,8 0.98 0.34 0.098 0.098b,d 31.8 29.3" 1.20 0.95b 0.22 0.25
(N = 10) (N = 10) (N = 6) (N = 6) (N = 10) (N = 10) (N = 10)
4,4 1.3 12.3 1.2 0.63 0.17 0.089 0.022
Table 3. Individual data of bone morphometry
Patients
TBV RS
% %
OS
%
ObS MOT DLS MR Svft Svf, BMU
%
.un % piday 3/p.2/day p.3//.L2/day
Als TA!
% mm/mm2
Bone a! ac
rate
mm/mm2/year
1 B 26.4 5.2 24.1 5.8 6.1 8.3 1.3 0.186 0.772 4.4 1.58 0.18
A 19.9 2.8 25.0 0.3 5.1 1 1.1 0.011 0.044 57.6 1.85 0.23
2 B 12.5 1.0 14.2 2.2 7.4 8.3 0.54 0.091 0.641 49.6 1.9 0.48
A 9.6 0.2 19.5 0 5.8 0 ND ND ND 75.6 1.82 0
3 B 29.6 4.0 58.5 13.8 11.3 9.2 0.90 0.165 0.282 13.2 0.72 0.18
A 27.2 0.2 57.0 4.5 8.5 1.5 1.20 0.102 0.179 50.3 1.26 0.61
4 B 26.0 9.6 40.4 19.6 12.4 NM NM NM NM 0 0 0
A 40.2 0.5 97.0 0.5 10.7 0 ND ND ND 0 0 0
5 B 17.1 7,7 58.5 26.0 15.3 35.5 1.5 0.813 1.390 33.8 1.82 0.18
A 15.8 0.4 56.5 0 8.7 0.8 0.4 0.009 0.016 68.2 2.93 0.67
6 B 21.2 9.8 37.6 21.3 12.1 27.9 0.92 0.456 1.213 2.4 0.65 0.09
A 32.0 4.5 43.0 7.3 11.2 8.6 0.97 0.123 0.286 30.7 1.94 0.60
7 B 29.0 8.5 50.2 8.4 12 11.7 0.93 0.182 0.296 0 0 0
A 37.5 1.0 44.0 3.1 5.8 0 ND ND ND 24.8 1.01 0.67
8 B 23.1 9.3 37 19.3 9.5 27.9 1.1 0.569 1.538 0 0 0
A 14.8 1.5 39 6.3 7.0 3.2 1.4 0.067 0.172 5 0.25 0.09
9 B 20.4 4.0 67.7 20.1 16.3 20 0.60 0.201 0.331 8.5 0.24 0.03
A 24.0 3.7 50.0 18.3 9.5 27 0.85 0.276 0.650 6.7 0.30 0.03
10 B 42.5 6.8 65.3 23.4 15.5 NM NM NM NM 0 0 0
A 34.5 0.5 92.5 0 15.5 0 ND ND ND 0 0 0
Normal range 18.0 0.37a 16.7a 8.8k 1l.P' 0.56b O.067b Ø,337b
(mean SD) 20.6a 0.65 19.1 6.3 10.2 13.5 0.80 0.101 0.657
Abbreviations: NM, not measurable because double labeling was not administrated; ND, not measurable because of the lack of any double-
labeled surface on the biopsy sample; B, before parathyroidectomy; A, after parathyroidectomy; for remaining abbreviations, see Table 2.
a The data are taken from Bordier and Tunchot [12].
b The data are taken from Melsen and Mosekilde [13].
decrease in the double-labeled surfaces, which parallel the
decrease in osteoblastic surfaces, whereas mineralization rate
was as high as before parathyroidectomy. The lack of correla-
tion between bone histology and serum iPTH after parathy-
roidectomy was disappointing. Having previously observed
such a correlation in a larger group of dialyzed patients [171, it
is possible this may be due to the lack of accuracy of the
immunoassay.
In bone, stainable aluminum has been shown to correlate
closely with biochemically determined aluminum [21. Stainable
aluminum deposit was increased after parathyroidectomy. Pre-
parathyroidectomy bone aluminum deposits were a major de-
terminant in the post-parathyroidectomy aluminum load. A
positive relation between pre- and post-parathyroidectomy alu-
minum deposits was observed. This increase in stainable alu-
minum could not be due to a simple passage of time because
there was no relationship between the time and the amount of
aluminum deposit neither before nor after parathyroidectomy.
Moreover, there was a higher aluminum accumulation rate after
parathyroidectomy when excluding the patients who received
no aluminum gel after parathyroidectomy and those who had no
decrease in bone formation rate. These two exclusion criteria
deserve more discussion.
Although there was no correlation between aluminum gel
intake and bone deposit after parathyroidectomy, the two
patients free of any aluminum deposit on the second bone
biopsy did not receive aluminum gel. The three patients without
aluminum gel intake after parathyroidectomy had no increase in
bone aluminum accumulation rate. It is now well established
that aluminum is absorbed from phosphate binders [20—21].
However, the increase in bone aluminum was not due to an
increase in aluminum gel intake as average aluminum gels were
decreased, It is unlikely that intestinal aluminum absorption
would have increased after parathyroidectomy, especially since
PTH has been shown, experimentally, not to have a role in
aluminum intestinal absorption [22—23]. Thus, it seems that if
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Fig. 4. Relation between aluminum-stained surftzces and trahecular
aluminum before and after parathyroidectomy, The two slopes are
different at P C 0.05. Symbols are: •—•, pre-PTX (r 0.66, y = 16.3x
+ 1.1); 0—0, post-PTX (r = 0.89, y = 26.Ix + 2.1).
some aluminum input is required for aluminum deposit occur-
rence after parathyroidectomy, the increase in bone aluminum
accumulation is not due to an increase in aluminum supply.
In patients who were taking aluminum or who had bone
aluminum deposits prior to parathyroidectomy, an increase in
bone aluminum occurred only in those patients who showed
decreased bone formation post-operatively. At present, there
are no data showing that decreased PTH secretion may directly
affect increased bone aluminum deposit. Furthermore, the
present clinical data do not concur with the observed enhanced
aluminum deposit in uremic rats injected with PTH [241. This
apparent discrepancy could be due either to the species differ-
ence or to the lack of inverse effect of PTH on bone aluminum
deposit. The mechanism of the bone aluminum deposition can
only be speculative. It is possible that a decreased formation
rate could facilitate a passive aluminum deposit.
Aluminum has been implicated in dialysis osteomalacia [1—21.
Aluminum administration induces in rats a pure osteomalacia
[1, 25, 26] or a decreased bone formation [27]. In dialyzed
patients massive bone aluminum load is associated with con-
stantly decreasing osteoblastic bone formation and sporadic
osteomalacia [2—41. In such cases the respective role of low
1PTH and bone aluminum accumulation in the decrease of bone
formation remains unclear. In the present study, six out of ten
patients had some aluminum deposits prior to parathyroidec-
tomy. This aluminum deposit is commonly observed among
patients with predominant secondary hyperparathyroidism, and
it does not induce any apparent deleterious effect on bone
formation or mineralization [4]. On the other hand, after
parathyroidectomy, we observed no relation between the alu-
minum deposits and decreased bone formation or mineraliza-
tion. After parathyroidectomy, the more predominant localiza-
tion of aluminum in so-called mineralization front, which has
been suggested to be of pathogenic importance [2], was not
associated with any mineralization defect. Furthermore, two
patients without aluminum deposits had a dramatically reduced
bone formation. Thus, when considering independently pre-
and post-parathyroidectomy results, no relation between bone
formation and aluminum deposit was observed. This result
might seem to be an apparent discrepancy with previous studies
performed on larger groups of unselected dialyzed patients
[2—4]. When considering pre- and post-parathyroidectomy re-
sults together, we could obtain a negative relation between
aluminum deposit and bone formation. However, this negative
relation does not exist when the independent factor,
parathyroidectomy, is considered, and thus, can hardly be
considered of pathogenic relevance.
In conclusion, parathyroidectomy resulted in pathologically
low bone formation in seven of ten patients. When there are
pre-existent aluminum deposits and/or aluminum gels are pre-
scribed, the decrease in bone formation observed is associated
with an increase in bone aluminum deposition rate. Thus, it
appears that low remodeling could facilitate bone aluminum
deposition. It is unclear whether in such circumstances, alumi-
num deposits play any role in the osteopathy observed.
Reprint requests to Dr. M. C. de Vernejoul, INSERM Unite 18,
Hópital Lariboisiere, 6 rue Guy Palm, 75010 Paris, France
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